PMID- 12140807
OWN - NLM
STAT- MEDLINE
DCOM- 20021105
LR  - 20191106
IS  - 1071-9164 (Print)
IS  - 1071-9164 (Linking)
VI  - 8
IP  - 3
DP  - 2002 Jun
TI  - The potential of brain natriuretic peptide as a biomarker for New York Heart 
      Association class during the outpatient treatment of heart failure.
PG  - 149-54
AB  - BACKGROUND: Plasma C-terminal atrial natriuretic peptide (C-ANP), N-terminal ANP 
      (N-ANP), and brain natriuretic peptide (BNP) have diagnostic utility in detecting 
      left ventricular dysfunction. Their relative value in monitoring symptom status 
      during the chronic treatment of congestive heart failure (CHF) remains undefined. 
      METHODS AND RESULTS: Ninety-eight subjects with CHF were evaluated. Baseline 
      natriuretic peptides were measured by radioimmunoassay, left ventricular ejection 
      fraction (LVEF) was estimated with echocardiography, and New York Heart 
      Association (NYHA) class was determined independently by attending heart failure 
      specialists. Forty-one subjects were restudied during a 6- to 12-month follow-up 
      period after optimizing therapy. At baseline, all natriuretic peptides and LVEF 
      correlated positively with NYHA class (P <.005). Plasma BNP, however, correlated 
      best with NYHA class. At follow-up, only changes of BNP correlated to changes of 
      NYHA class (P =.04). BNP decreased (-45% +/- 12%, N = 14, P =.002) in subjects 
      whose NYHA class improved whereas BNP remained unchanged (-1% +/- 10%, N = 25, P 
      =.95) in those whose NYHA class was stable. CONCLUSIONS: This investigation 
      demonstrates the superiority of plasma BNP as compared to ANP and LVEF in 
      objectively assessing NYHA class during the chronic treatment of CHF. Given that 
      clinical assessment of CHF is subjective, plasma BNP is a useful objective 
      biomarker in monitoring human CHF in the outpatient setting.
FAU - Lee, Shang-Chiun
AU  - Lee SC
AD  - Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo 
      Clinic, Rochester, Minnesota 55905, USA.
FAU - Stevens, Tracy L
AU  - Stevens TL
FAU - Sandberg, Sharon M
AU  - Sandberg SM
FAU - Heublein, Denise M
AU  - Heublein DM
FAU - Nelson, Susan M
AU  - Nelson SM
FAU - Jougasaki, Michihisa
AU  - Jougasaki M
FAU - Redfield, Margaret M
AU  - Redfield MM
FAU - Burnett, John C Jr
AU  - Burnett JC Jr
LA  - eng
GR  - HL 07111/HL/NHLBI NIH HHS/United States
GR  - HL 36634/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Biomarkers)
RN  - 0 (N-terminal proatrial natriuretic peptide)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 111863-73-1 (atrial natriuretic factor (4-23)NH2, 
      de-Gln(18)-de-Ser(19)-de-Gly(20,22)-de-Leu(21)-)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care
MH  - Atrial Natriuretic Factor/*blood
MH  - Biomarkers/blood
MH  - Female
MH  - Heart Failure/*blood/classification/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Protein Precursors/*blood
MH  - Radioimmunoassay
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/*blood
EDAT- 2002/07/26 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/07/26 10:00
PHST- 2002/07/26 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/07/26 10:00 [entrez]
AID - S1071916402000064 [pii]
AID - 10.1054/jcaf.2002.125368 [doi]
PST - ppublish
SO  - J Card Fail. 2002 Jun;8(3):149-54. doi: 10.1054/jcaf.2002.125368.